Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research ...

Bruker posts higher-than-expected Q1 revenue and announces NGS collaboration with Ridom to boost microbiology and infection ...

Bruker Corporation BRKR has introduced an innovative Fourier 80 multinuclear benchtop FT-Nuclear Magnetic Resonance (NMR) spectrometer, known as the ‘Multi-Talent’ configuration. Unveiled at the Joint ...

Bruker expects first-quarter revenue to be $795 million to $800 million, ahead of Wall Street expectations. Analysts polled by FactSet are forecasting $758.4 million in quarterly revenue. The ...

The company said, “This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage ...

Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company’s ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of ...

Controlling film thickness to precise specifications is essential for ensuring high yield in high-performance devices.

Bruker Corporation’s BRKR share price has dipped by 11.48%, which has investors questioning if this is right time to buy.

Bruker Corporation ( NASDAQ:BRKR ), is not the largest company out there, but it received a lot of attention from ...

Detailed price information for Mettler-Toledo International (MTD-N) from The Globe and Mail including charting and trades.

Discover how Bruker’s BRAVO handheld Raman spectrometer is transforming material analysis with advanced fluorescence suppression and more.